A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial

The Hippo pathway effector YAP is dysregulated in malignant pleural mesothelioma (MPM). YAP's target genes include the secreted growth factor amphiregulin (AREG), which is overexpressed in a wide range of epithelial cancers and plays an elusive role in MPM. We assayed the expression of YAP and...

Descripción completa

Detalles Bibliográficos
Autores principales: Maille, Elodie, Levallet, Jérôme, Dubois, Fatéméh, Antoine, Martine, Danel, Claire, Creveuil, Christian, Mazieres, Julien, Margery, Jacques, Greillier, Laurent, Gounant, Valérie, Moro‐Sibilot, Denis, Molinier, Olivier, Léna, Hervé, Monnet, Isabelle, Bergot, Emmanuel, Langlais, Alexandra, Morin, Franck, Scherpereel, Arnaud, Zalcman, Gérard, Levallet, Guénaëlle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Molecular Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545369/
https://www.ncbi.nlm.nih.gov/pubmed/35262190
http://dx.doi.org/10.1002/ijc.33997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545369/
https://www.ncbi.nlm.nih.gov/pubmed/35262190
http://dx.doi.org/10.1002/ijc.33997

Ejemplares similares